Email Print Share

Directorate for Engineering


NSF/FDA SCHOLAR-IN-RESIDENCE AT FDA


CONTACTS
Name Email Phone Room
Leon  Esterowitz lesterow@nsf.gov (703) 292-7942  565S  
Joel  Myklebust nsf.sir@fda.hhs.gov (301) 796-2491   
Helen  Gill hgill@nsf.gov (703) 292-8950  1175N  


PROGRAM GUIDELINES

Solicitation  10-533

Important Information for Proposers

ATTENTION: Proposers using the Collaborators and Other Affiliations template for more than 10 senior project personnel will encounter proposal print preview issues. Please see the Collaborators and Other Affiliations Information website for updated guidance.

A revised version of the NSF Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 18-1), is effective for proposals submitted, or due, on or after January 29, 2018. Please be advised that, depending on the specified due date, the guidelines contained in NSF 18-1 may apply to proposals submitted in response to this funding opportunity.


DUE DATES

Full Proposal Accepted Anytime


SYNOPSIS

The National Science Foundation (NSF), through the Directorate for Engineering's Division of Chemical, Bioengineering, Environmental, and Transport Systems (CBET), and the U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH) have established the NSF/FDA Scholar-in-Residence Program at FDA. This program comprises an interagency partnership for the investigation of scientific and engineering issues concerning emerging trends in medical device technology. This partnership is designed to enable investigators in science, engineering, and mathematics to develop research collaborations within the intramural research environment at the FDA. This solicitation features four flexible mechanisms for support of research at the FDA: 1) Faculty at FDA; 2) Graduate Student Fellowships; 3) Postdoctoral Fellowships; and, 4) Undergraduate Student Research Experiences. Undergraduate student participants supported with NSF funds must be citizens or permanent residents of the United States.